An observational study in Depressed Mood, sponsored by Salma Health, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Salma Health, Inc. · Observational
This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings. The study will examine outcomes among patients treated with interventions including esketamine, conventional transcranial magnetic stimulation (TMS), or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). Retrospective clinical and research data from existing databases may also be incorporated, when available and authorized, to support model development and validation. The goal is to assess whether integrated clinical datasets can be used to support the development of predictive tools that may inform personalized treatment selection in depression.
236 studies on the registry are indexed under Consciousness Disorders; 102 are open to participants now.
This study's planned enrollment of 5,000 is above the median of 79 across 86 observational studies indexed under Consciousness Disorders.
Browse Consciousness Disorders studies →This is the only study on the registry with Salma Health, Inc. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
This study will enroll up to 5,000 adult participants who are presenting for care with depressed mood and are prescribed and intending to receive standard-of-care treatment with esketamine, conventional TMS or SAINT.
Exclusion Criteria:
Patients receiving esketamine for the treatment of depressed mood.
Patients receiving conventional rTMS for the treatment of depressed mood.
Patients receiving SAINT for the treatment of depressed mood.
Patient Health Questionnaire 9-item (PHQ-9)
The Patient Health Questionnaire (PHQ-9) is a 9-item multipurpose self-report instrument for screening, diagnosing, monitoring and measuring the severity of depression.
Time frame: Pre-treatment, Post-treatment, 2 weeks posttreatment, and Monthly post-treatment for 12 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.